Search
Interferon alfa-2b
go.drugbank.com/drugs/DB00105ApprovedInvestigationalIt is used extensively as an antiviral or antineoplastic agent.
Mixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)Products: VIRAFERON INYECTABLE 3 MILLONES IUDeuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigational[A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata. … [L51083] Alopecia areata is an autoimmune condition that attacks the hair follicles and leads to unpredictable hair loss in the scalp and other areas of the body.
Synonyms: D8-ruxolitinib, -(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-, (.beta.r)-Denosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigational; Both biosimilars also received marketing authorization in the EU in May 2024. … [A263066] An Denosumab biosimilar, Jubbonti, was approved for Health Canada in February 2024.[L52083].
International brands: RanmarkCrizanlizumab
go.drugbank.com/drugs/DB15271ApprovedInvestigationalIt was developed by Novartis and was granted FDA approval on November 15, 2019. … Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels.
Delamanid
go.drugbank.com/drugs/DB11637ApprovedInvestigationalDelamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall [A31965].
Dilmapimod
go.drugbank.com/drugs/DB12140InvestigationalMethotrexate (common treatment for RA patients) also has potential liver toxicity.} … Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis).
Sotatercept
go.drugbank.com/drugs/DB12118ApprovedInvestigationalSotatercept is an activin signalling inhibitor. … [L50351] On March 26, 2024, sotatercept was approved by the FDA for the treatment of pulmonary arterial hypertension (PAH).
Zoliflodacin
go.drugbank.com/drugs/DB12817ApprovedInvestigationalGonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance. … FDA in December 2025, following Fast Track, Qualified Infectious Disease Product, and Priority Review designations.[L54743,L54803]
Isotretinoin
go.drugbank.com/drugs/DB00982ApprovedInvestigational[L6579] The first isotretinoin-containing product was FDA approved on 7 May 1982.[L6574]
Synonyms: 13-RA, 13-cRAProducts: Ran-isotretinoin